CClinicalTrials.gg
WithdrawnNCT00375349Updated Sep 30, 2016

Non Alcoholic Fatty Liver Disease Influence of Statin Therapy

An interventional study of Ultrasound to demonstrate existence of fatty liver in Non-alcoholic Fatty Liver Disease (NAFLD), sponsored by Shaare Zedek Medical Center. Withdrawn. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-09-30.

Sponsored by Shaare Zedek Medical Center · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
0
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Aim:

  1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.
  2. To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.
Read the detailed description

Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.

Serum samples will be frozen and kept for future ongoing research.

02

Conditions studied

  • Non-alcoholic Fatty Liver Disease (NAFLD)

Keywords

  • fatty liver
  • statin
  • non-alcoholic
03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.

Browse Liver Diseases studies →

Lead sponsor

Shaare Zedek Medical Center is the lead sponsor of 191 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Cardiology patient
  • Age above 18

Exclusion criteria

Exclusion Criteria:

  • Age below 18
05

Study design

Phase
Not applicable
Enrollment
0 participants (actual)

Interventions

  • ProcedureUltrasound to demonstrate existence of fatty liver
06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006 Jan;184(1):233-4. doi: 10.1016/j.atherosclerosis.2005.08.021. Epub 2005 Oct 5. No abstract available. PubMed 16168995 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00375349
Lead sponsor
Shaare Zedek Medical Center
First posted
Sep 12, 2006
Start date
Sep 2006
Completion
Sep 2009 (estimated)
Last update
Sep 30, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion